Literature DB >> 9376836

Rehabilitation of patients with anosognosia for hemiplegia due to intracerebral haemorrhage.

S Maeshima1, N Dohi, K Funahashi, K Nakai, T Itakura, N Komai.   

Abstract

We have studied the differences in the lesions, concomitant symptoms and ADL levels in patients in acute-stage cerebral-haemorrhage and manifesting anosognosia. Twelve of 50 patients (24.0%) presented with anosognosia. The (+) group had longer intervals between onset and the first evaluation than did the (-) group, demonstrating severe sensory disturbance. The volume of haemorrhage was significantly larger in the (+) group. Anosognosia disappeared within 3 months in all cases. In the (+) group the time until discharge was long, with the ADL level at the time of discharge being low. Therefore, it was considered that anosognosia was important as an inhibitory factor hampering rehabilitation.

Entities:  

Mesh:

Year:  1997        PMID: 9376836     DOI: 10.1080/026990597123232

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  4 in total

1.  Incidence and diagnosis of anosognosia for hemiparesis revisited.

Authors:  B Baier; H-O Karnath
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

2.  Anosognosia for hemiplegia: The contributory role of right inferior frontal gyrus.

Authors:  Kathleen B Kortte; Jessica Wolfman McWhorter; Mikolaj A Pawlak; Jamie Slentz; Sandeepa Sur; Argye E Hillis
Journal:  Neuropsychology       Date:  2014-08-18       Impact factor: 3.295

3.  Recent trends in rehabilitation interventions for visual neglect and anosognosia for hemiplegia following right hemisphere stroke.

Authors:  Kathleen B Kortte; Argye E Hillis
Journal:  Future Neurol       Date:  2011-01-01

Review 4.  Recent advances in the understanding of neglect and anosognosia following right hemisphere stroke.

Authors:  Kathleen Kortte; Argye E Hillis
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.